Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brain endothelial cells orchestrate a neuroprotective antiviral state in the CNS in response to peripheral viral pattern sensing.

Immunity·2026
Same author

A distinct E dimer epitope underlies selective recognition by a protective human West Nile virus antibody.

EMBO reports·2026
Same author

Estimating the in vivo prophylactic effect of mosnodenvir, a novel dengue antiviral, on DENV-2 infection.

Journal of the Royal Society, Interface·2026
Same author

Asymmetric structural transitions in the icosahedral organization of Eastern equine encephalitis virus.

Nature communications·2026
Same author

Human antibody targeting Crimean-Congo hemorrhagic fever virus glycoprotein 38 protects mice against heterologous virus challenge.

The Journal of clinical investigation·2026
Same author

Epitope-focused discovery of SARS-CoV-2 antibodies that potently neutralize Omicron variants.

Nature microbiology·2026

Related Experiment Video

Updated: Dec 25, 2025

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination
15:25

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination

Published on: July 4, 2007

18.9K

E. coli production process yields stable dengue 1 virus-sized particles (VSPs).

Janet Hirsch1, Bart W Faber2, James E Crowe3

  • 1Hamburg University of Applied Sciences, Ulmenliet 20, 21033 Hamburg, Germany.

Vaccine
|March 22, 2020
PubMed
Summary

Researchers developed dengue virus-sized particles (VSPs) from recombinant E protein. These particles showed potential but did not induce neutralizing antibodies in rabbits, indicating a need for structural optimization for vaccine development.

Keywords:
DengueDynamic light scatteringE. coliStabilityVirus-like particleVirus-sized particle

More Related Videos

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

7.5K
The MultiBac Protein Complex Production Platform at the EMBL
13:51

The MultiBac Protein Complex Production Platform at the EMBL

Published on: July 11, 2013

16.5K

Related Experiment Videos

Last Updated: Dec 25, 2025

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination
15:25

Protocol for Dengue Infections in Mosquitoes A. aegypti and Infection Phenotype Determination

Published on: July 4, 2007

18.9K
Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors
14:55

Production and Purification of Non Replicative Canine Adenovirus Type 2 Derived Vectors

Published on: December 3, 2013

7.5K
The MultiBac Protein Complex Production Platform at the EMBL
13:51

The MultiBac Protein Complex Production Platform at the EMBL

Published on: July 11, 2013

16.5K

Area of Science:

  • Virology
  • Vaccine Development
  • Protein Engineering

Background:

  • Dengue fever is a widespread vector-borne disease with significant global morbidity and economic impact.
  • Current dengue vaccines offer limited protection, necessitating the development of more effective and cost-efficient alternatives.
  • The dengue virus E protein is a key target for vaccine design due to its role in viral entry and immunogenicity.

Purpose of the Study:

  • To produce and characterize recombinant dengue serotype 1 E protein as a potential vaccine candidate.
  • To assess the structural integrity and stability of the refolded E protein particles.
  • To evaluate the immunogenicity of the generated particles in a preclinical rabbit model.

Main Methods:

  • Recombinant dengue serotype 1 E protein was expressed in E. coli and purified.
  • Virus-like particles (VLPs) were formed by refolding the purified protein.
  • Particle characterization involved size-exclusion chromatography, dynamic light scattering (DLS), transmission electron microscopy (TEM), atomic force microscopy, and stimulated emission depletion (STED) fluorescence microscopy.
  • Particle stability was assessed under varying temperature and pH conditions.
  • Immunogenicity was tested by immunizing rabbits and measuring neutralizing antibody titers.

Main Results:

  • Recombinant E protein was successfully produced and refolded into virus-sized particles (VSPs).
  • Particle assembly and size were influenced by temperature, pH, buffer composition, and L-arginine.
  • VSPs demonstrated stability at pH 9.5 and higher at 4°C and tolerance to short-term heat exposure up to 55°C.
  • Structural analyses indicated that the obtained particles were not optimal VLPs.
  • Immunization with VSPs did not elicit neutralizing antibodies in rabbits, although antibodies recognized the native virus.

Conclusions:

  • The generated virus-sized particles (VSPs) from dengue serotype 1 E protein require further structural refinement for optimal vaccine potential.
  • Particle stability and assembly are sensitive to environmental factors, necessitating careful optimization.
  • The lack of neutralizing antibody induction suggests conformational differences between VSPs and native virions, highlighting the challenge in developing conformationally accurate VLPs.
  • Ongoing studies aim to improve VSP quality to achieve true virus-like particles for enhanced dengue vaccine candidates.